Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by dacha8881on Mar 29, 2010 11:42am

432 Views

Post# 16935071

RE: RE: $8 Bucks

If it is true that RVX wants 1.5 billion for this, this would translate, roughly, to around $33-$35 a share. How did you calculate the $60?
I do realize that a few years ago Don had said that he wouldn't sell for less than $60 a share but the only info I have so far is the $1.5 billion figure. Does anyone here has "new" information regarding the price negotiations?
Personally, I'd say hold on for more money :-) but if we end up owning shares in the buyer's company (often the case in negotiated buyouts), perhaps all will be good with possible endless "royalties" ...
Go, RVX, go!

Bullboard Posts

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project